Studies have shown that EZH2 overexpression is strongly associated with poor prognosis in prostate and breast cancers.828 Loss-of-function mutations in the EZH2 gene in myeloid malignancies and T cell acute lymphoblastic leukemia (T-ALL) also lead to poor prognosis.839. Here, EZH2 is linked to breast cancer.